Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | FPR2 | P25090 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025662 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL7441174 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2933768 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL22210773 | 0.96 | ALDH1A1 (0.54) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL29577673 | 0.96 | ALDH1A1 (0.54) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30011128 | 0.96 | ALDH1A1 (0.54) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2739558 | 0.94 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL29707133 | 0.93 | ALDH1A1 (0.51) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL4982161 | 0.93 | ALDH1A1 (0.51) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL29906310 | 0.93 | ALDH1A1 (0.51) | ALDH1A1ENPEPL3MBTL1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-103163269-B | Method for fast identifying fermented soy sauce and blended soy sauce | FOSHAN HAITIAN FLAVORING & FOOD CO LTD | 2014-12-17 | — | — | CN | claimed |
| CN-103163248-B | Method for identifying blended soy sauce | FOSHAN HAITIAN FLAVORING & FOOD CO LTD | 2014-05-28 | — | — | CN | claimed |
| CN-103163248-A | Method for identifying blended soy sauce | FOSHAN HAITIAN FLAVORING & FOOD CO LTD | 2013-06-19 | — | — | CN | claimed |
| CN-103163269-A | Method for fast identifying fermented soy sauce and blended soy sauce | FOSHAN HAITIAN FLAVORING & FOOD CO LTD | 2013-06-19 | — | — | CN | claimed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2024-04-11 | — | — | US | disclosed |
| CN-117384766-A | Aspergillus amsterdam S01 and application thereof | 商洛学院 | 2024-01-12 | — | — | CN | disclosed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3650852-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-10690651-B2 | Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200194126-A1 | SYSTEMS AND METHODS FOR PROFILING AND CLASSIFYING HEALTH-RELATED FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-18 | — | — | US | disclosed |
| CN-1016341-B | NOVEL SPERGUALIN-RELATED COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | MICROBIAL CHEMICAL RESEARCHING (JP) | 1992-04-22 | — | — | CN | disclosed |
| US-5061787-A | IMMUNOSUPPRESSANTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0241797-B1 | NOVEL SPERGUALIN-RELATED COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4956504-A | IMMUNOMODULATORS, ANTIBIOTICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1990-09-11 | — | — | US | disclosed |
| EP-0347820-A1 | Novel spergualin-related compounds and preparation and application of the same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0309971-A2 | New spergualin-related compound and pharmaceutical composition | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1989-04-05 | — | — | EP | disclosed |
| CN-87102538-A | New compound relevant and preparation method thereof with spergualin | — | 1987-11-18 | — | — | CN | disclosed |
| EP-0241797-A2 | Novel spergualin-related compounds and process for producing the same | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, ACADM | ALDH1A1 603/4885ENPEP 979/4885L3MBTL1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.